SCINAI IMMUNOTHERAPEUTICS LTD. — Operating Income by Fiscal Year
5 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/7791b07b-f4c4-4a26-aff2-711734861dab/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-7.5M | 2025-01-01 – 2025-12-31 | evidence 0001213900-26-038011 |
| FY 2024 | $-8.6M | 2024-01-01 – 2024-12-31 | evidence 0001213900-25-040402 |
| FY 2023 | $-9.7M | 2023-01-01 – 2023-12-31 | evidence 0001213900-25-040402 |
| FY 2022 | $-11.1M | 2022-01-01 – 2022-12-31 | evidence 0001213900-23-030228 |
| FY 2021 | $-10.9M | 2021-01-01 – 2021-12-31 | evidence 0001213900-23-030228 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).